The Life Sciences Innovative Manufacturing Fund (LSIMF) is part of the Global Britain Investment Fund and will provide £60 million in capital grants for investment in the manufacture of:
- human medicines (drug substance and drug product)
- medical diagnostics
- MedTech products
The first tranche of companies to be supported by LSIMF have already been announced and are now re-opening the fund with the remaining budget of £7.6 million.
Specific themes
They particularly welcome applications from companies with manufacturing investments that demonstrate the adoption of innovative process technologies, for example:
- flexible manufacturing enabling rapid product switching
- continuous manufacturing
- technologies that will minimise impact of the product or the manufacturing process on the environment
- digital twins, which harness the power of data analytics and modelling to optimise manufacturing processes
This list is not exhaustive.
Details of how to express your interest and eligibility requirements are available on the website. The deadline for expression of interest is noon on Tuesday 30 May.
